Product
Trivalent Influenza Vaccine 2 SP Shz TIV2
1 clinical trial
1 indication
Indication
InfluenzaClinical trial
Immunogenicity and Safety of the Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of AgeStatus: Completed, Estimated PCD: 2020-12-01